Intellia Therapeutics (NTLA) Capital Expenditures (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Capital Expenditures of $126000.0 for Q4 2025, down 37.93% year-over-year from $203000.0 in Q4 2024, and down 87.44% quarter-over-quarter from $1.0 million in Q3 2025.
Intellia Therapeutics (NTLA) Capital Expenditures (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Capital Expenditures for 11 consecutive years, with $126000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures fell 37.93% year-over-year to $126000.0; the TTM figure through Mar 2026 stood at $1.0 million (up 156.69% YoY), while the FY2025 annual figure was $1.1 million, up 95.67% from the prior year.
- Capital Expenditures fell to $126000.0 in Q4 2025 per NTLA's latest filing, from $1.0 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.6 million in Q2 2023 and bottomed at -$10.9 million in Q4 2023.
- Historically, Capital Expenditures has averaged $880500.0 across 5 years, with a median of $552000.0 in 2021.
- On a YoY basis, Capital Expenditures climbed as much as 15789.66% in 2023 and fell as far as 1864.09% in 2023.
- Intellia Therapeutics' Capital Expenditures stood at $2.9 million in 2021, then sank by 119.42% to -$557000.0 in 2022, then tumbled by 1864.09% to -$10.9 million in 2023, then soared by 101.86% to $203000.0 in 2024, then tumbled by 37.93% to $126000.0 in 2025.
- Business Quant data shows NTLA's Capital Expenditures at $126000.0 in Q4 2025, $1.0 million in Q3 2025, and -$82000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.81 Mn |
| Jun 30, 2026 | 1.81 Mn |
| Mar 31, 2026 | 79,000.00 |
| Mar 31, 2026 | 79,000.00 |
| Dec 31, 2025 | 126,000.00 |
| Dec 31, 2025 | 126,000.00 |
| Sep 30, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | -82,000.00 |
| Jun 30, 2025 | -82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Sep 30, 2024 | -257,000.00 |
| Sep 30, 2024 | -257,000.00 |
| Jun 30, 2024 | -1.88 Mn |
| Jun 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Mar 31, 2024 | 2.51 Mn |